Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-IL21 Recombinant Antibody (CBYY-I1052) (CBMAB-I2220-YY)

Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human, Mouse
Clone
CBYY-I1052
Antibody Isotype
IgG1, κ
Application
WB

Basic Information

Specificity
Human, Mouse
Antibody Isotype
IgG1, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
PBS, pH 7.2
Preservative
0.09% sodium azide
Concentration
0.5 mg/ml
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
interleukin 21
Introduction
This gene encodes a member of the common-gamma chain family of cytokines with immunoregulatory activity. The encoded protein plays a role in both the innate and adaptive immune responses by inducing the differentiation, proliferation and activity of multiple target cells including macrophages, natural killer cells, B cells and cytotoxic T cells. Dysregulation of this gene plays a role in multiple immune-mediated diseases including lupus, psoriasis and chronic inflammatory diseases. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.
Entrez Gene ID
Human59067
Mouse60505
UniProt ID
HumanQ9HBE4
MouseQ9ES17
Alternative Names
Interleukin 21
Function
Cytokine with immunoregulatory activity. May promote the transition between innate and adaptive immunity. Induces the production of IgG(1) and IgG(3) in B-cells (By similarity).
Implicated in the generation and maintenance of T follicular helper (Tfh) cells and the formation of germinal-centers. Together with IL6, control the early generation of Tfh cells and are critical for an effective antibody response to acute viral infection (By similarity).
May play a role in proliferation and maturation of natural killer (NK) cells in synergy with IL15. May regulate proliferation of mature B- and T-cells in response to activating stimuli. In synergy with IL15 and IL18 stimulates interferon gamma production in T-cells and NK cells (PubMed:11081504, PubMed:15178704).
During T-cell mediated immune response may inhibit dendritic cells (DC) activation and maturation (By similarity).
Biological Process
MaturationManual Assertion Based On ExperimentIDA:UniProtKB
Cellular response to virusISS:UniProtKB
Defense response to virusManual Assertion Based On ExperimentTAS:ARUK-UCL
Germinal center B cell differentiationISS:UniProtKB
Positive regulation of B cell proliferationManual Assertion Based On ExperimentIDA:MGI
Positive regulation of cell population proliferationManual Assertion Based On ExperimentIDA:MGI
Positive regulation of cytokine productionManual Assertion Based On ExperimentIDA:CACAO
Positive regulation of immunoglobulin productionISS:UniProtKB
Positive regulation of inflammatory response1 PublicationIC:BHF-UCL
Positive regulation of interferon-gamma production1 PublicationNAS:UniProtKB
Positive regulation of interleukin-17 productionManual Assertion Based On ExperimentIDA:BHF-UCL
Positive regulation of natural killer cell mediated cytotoxicityManual Assertion Based On ExperimentIDA:CACAO
Positive regulation of T cell proliferationManual Assertion Based On ExperimentIDA:UniProtKB
Positive regulation of tissue remodeling1 PublicationIC:BHF-UCL
Positive regulation of tyrosine phosphorylation of STAT proteinManual Assertion Based On ExperimentIDA:MGI
Signal transduction1 PublicationNAS:UniProtKB
T follicular helper cell differentiationISS:UniProtKB
Tyrosine phosphorylation of STAT proteinManual Assertion Based On ExperimentIDA:CACAO
Cellular Location
Secreted
Involvement in disease
Immunodeficiency, common variable, 11 (CVID11):
A primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low.
More Infomation

Nguyen, R., Zhang, X., Sun, M., Abbas, S., Seibert, C., Kelly, M. C., ... & Thiele, C. J. (2022). Anti-Gd2 antibodies conjugated to IL15 and IL21 mediate potent antitumor cytotoxicity against neuroblastoma. Clinical Cancer Research, 28(17), 3785-3796.

Loucif, H., Dagenais-Lussier, X., Avizonis, D., Choinière, L., Beji, C., Cassin, L., ... & van Grevenynghe, J. (2022). Autophagy-dependent glutaminolysis drives superior IL21 production in HIV-1-specific CD4 T cells. Autophagy, 18(6), 1256-1273.

Hao, H., Nakayamada, S., Ohkubo, N., Yamagata, K., Zhang, M., Shan, Y., ... & Tanaka, Y. (2021). Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus. Arthritis Research & Therapy, 23(1), 302.

Wu, S., Sun, R., Tan, B., Chen, B., Zhou, W., Gao, D. S., ... & Lu, B. (2021). The half-life-extended IL21 can be combined with multiple checkpoint inhibitors for tumor immunotherapy. Frontiers in Cell and Developmental Biology, 9, 779865.

Gonzalez-Junca, A., Liu, F. D., Nagaraja, A. S., Mullenix, A., Lee, C. T., Gordley, R. M., ... & Lee, G. (2021). SENTI-101, a preparation of mesenchymal stromal cells engineered to express IL12 and IL21, induces localized and durable antitumor immunity in preclinical models of peritoneal solid tumors. Molecular Cancer Therapeutics, 20(9), 1508-1520.

Wang, J., Hasan, F., Frey, A. C., Li, H. S., Park, J., Pan, K., ... & Yee, C. (2020). Histone deacetylase inhibitors and IL21 cooperate to reprogram human effector CD8+ T cells to memory T cells. Cancer immunology research, 8(6), 794-805.

Batra, S. A., Rathi, P., Guo, L., Courtney, A. N., Fleurence, J., Balzeau, J., ... & Heczey, A. (2020). Glypican-3–specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer immunology research, 8(3), 309-320.

Ciszewski, C., Discepolo, V., Pacis, A., Doerr, N., Tastet, O., Mayassi, T., ... & Jabri, B. (2020). Identification of a γc receptor antagonist that prevents reprogramming of human tissue-resident cytotoxic T cells by IL15 and IL21. Gastroenterology, 158(3), 625-637.

Desmots, F., Roussel, M., Pangault, C., Llamas-Gutierrez, F., Pastoret, C., Guiheneuf, E., ... & Fest, T. (2019). Pan-HDAC inhibitors restore PRDM1 response to IL21 in CREBBP-mutated follicular lymphoma. Clinical Cancer Research, 25(2), 735-746.

Seo, H., Kim, B. S., Bae, E. A., Min, B. S., Han, Y. D., Shin, S. J., & Kang, C. Y. (2018). IL21 therapy combined with PD-1 and Tim-3 blockade provides enhanced NK cell antitumor activity against MHC class I–deficient tumors. Cancer immunology research, 6(6), 685-695.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-IL21 Recombinant Antibody (CBYY-I1052)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Online Inquiry